Aripiprazole in Children and Adolescents With Bipolar I Disorder

This study has been completed.
Sponsor:
Information provided by:
Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier:
NCT00110461
First received: May 9, 2005
Last updated: April 19, 2012
Last verified: April 2012
  Purpose

The purpose of this trial is to test the safety and efficacy of two doses of aripiprazole in child and adolescent patients with bipolar I disorder, manic or mixed episode with or without psychotic features.


Condition Intervention Phase
Bipolar Disorder
Drug: Aripiprazole
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III Trial to Test the Safety and Efficacy of Two Doses of Aripiprazole in Child and Adolescent Patients With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features

Resource links provided by NLM:


Further study details as provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:

Primary Outcome Measures:
  • Change in Young Mania Rating Scale (Y-MRS) Total Score at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]

    Change from Baseline to Week 4 in Y-MRS total score, using the last observation carried forward.

    Assessments performed at baseline and weekly through the acute phase (Week 4). (Also performed at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through the continuation phase.)

    The Y-MRS consists of 11 items assessing the core symptoms of mania. Each item has 5 grades of severity. Minimum score on the scale is 0 (absent or normal). Maximum score on the scale is 60 (worse outcome or more severe symptoms).



Secondary Outcome Measures:
  • Change in Young Mania Rating Scale (Y-MRS) Total Score at Week 30 [ Time Frame: Baseline and Week 30 ] [ Designated as safety issue: No ]

    Change from baseline to Week 30 in Y-MRS total score, using the last observation carried forward.

    Assessments performed at baseline and weekly through the acute phase (Week 4) and at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase.

    The Y-MRS consists of 11 items assessing the core symptoms of mania. Each item has 5 grades of severity. Minimum score on the scale is 0 (absent or normal). Maximum score on the scale is 60 (worse outcome or more severe symptoms).


  • Change in Children's Global Assessment Scale (CGAS) Total Score at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]

    Change from baseline to Week 4 in CGAS total score, using the last observation carried forward. Assessments performed at baseline and weekly through the acute phase (Week 4). (Also performed at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase.)

    The CGAS is a 100-point scale measuring psychological, social, and school functioning for children aged 6 to 17 years. Minimum scores ranged from 1-10, representing the need for constant supervision (worse outcome) to maximum scores of 91-100, representing superior functioning (better outcome).


  • Change in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Mania Score at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]

    Change from baseline to Week 4 in CGI-BP mania score, using the last observation carried forward.

    Assessments performed at baseline and weekly through the acute phase (Week 4). (Also performed at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase.)

    The CGI-BP scale refers to the global impression of the subject with respect to bipolar disorder. The scale rates the subject's severity of illness for mania, depression, and overall bipolar illness from 1 (least severe) to 7 (most severe).


  • Change in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
    Change from baseline to Week 4 in CDRS-R score, using last observation carried forward. Assessments performed at baseline and weekly through the acute phase (Week 4). (Also performed at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase.) The CDRS-R is used to diagnose depression and monitor treatment response. The interviewer rates 17 symptom areas (including those that sever as DSM-IV criteria for diagnosis of depression), among them suicidal ideation. Minimum score on the scale is 17 (better outcome). Maximum score on the scale is 113 (worse outcome or more severe symptoms).

  • Change in General Behavior Inventory Scale (GBI) Total Parent/Guardian Version Mania Score at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
    Change from baseline to Week 4 in GBI Total Parent/Guardian Version Mania score, using LOCF. Assessments performed baseline and weekly through acute phase (Week 4). (Also at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase.) GBI is self-report inventory with 73 items focused on mood-related behaviors including depressive, hypomanic, and biphasic symptoms. One 20-item subscale was completed by parent/guardian. Symptoms rated on a 4-point Likert scale from 0 (never or hardly ever) to 3 (often or almost constantly). Minimum score 0=better outcome, maximum score 60=worse outcome.

  • Change in Attention Deficit Hyperactivity Disorders Rating Scale (ADHD-RS-IV) Total Score at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
    Change from baseline to Week 4 in ADHD-RS-IV Total score, using last observation carried forward. Assessments performed at baseline and weekly through acute phase (Week 4). (Also performed at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase.) ADHD-RS-IV is an instrument for diagnosing ADHD in children/adolescents and for assessing treatment response. The scale contains 18 items linked directly to DSM-IV diagnostic criteria for ADHD. Parent questionnaire on home behaviors (Eng.) used in this study. Minimum score of 0 is a better outcome, maximum score of 54 is a worse outcome.

  • Change in Children's Global Assessment (CGAS) Total Score at Week 30 [ Time Frame: Baseline and Week 30 ] [ Designated as safety issue: No ]

    Change from baseline to Week 30 in CGAS total score, using the last observation carried forward.

    Assessments performed at baseline and weekly through the acute phase (Week 4) and at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase.

    The CGAS is a 100-point scale measuring psychological, social, and school functioning for children aged 6 to 17 years. Minimum scores ranged from 1-10, representing the need for constant supervision (worse outcome) to maximum scores of 91-100, representing superior functioning (better outcome).


  • Change in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Mania Score at Week 30 [ Time Frame: Baseline and Week 30 ] [ Designated as safety issue: No ]

    Change from baseline to Week 30 in CGI-BP mania score, using the last observation carried forward.

    Assessments performed at baseline and weekly through the acute phase (Week 4) and at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase.

    The CGI-BP scale refers to the global impression of the subject with respect to bipolar disorder. The scale rates the subject's severity of illness for mania, depression, and overall bipolar illness from 1 (least severe) to 7 (most severe).


  • Change in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Depression Score at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]

    Change from baseline to Week 4 in CGI-BP severity depression score, using the last observation carried forward.

    Assessments performed at baseline and weekly through the acute phase (Week 4. (Also performed at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase.)

    The CGI-BP scale refers to the global impression of the subject with respect to bipolar disorder. The scale rates the subject's severity of illness for mania, depression, and overall bipolar illness from 1 (least severe) to 7 (most severe).


  • Change in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Depression Score at Week 30 [ Time Frame: Baseline and Week 30 ] [ Designated as safety issue: No ]

    Change from baseline to Week 30 in CGI-BP severity depression score, using the last observation carried forward.

    Assessments performed at baseline and weekly through the acute phase (Week 4) and at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase.

    The CGI-BP scale refers to the global impression of the subject with respect to bipolar disorder. The scale rates the subject's severity of illness for mania, depression, and overall bipolar illness from 1 (least severe) to 7 (most severe).


  • Change in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Overall Illness Score at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]

    Change from baseline to Week 4 in CGI-BP severity overall illness score, using the last observation carried forward.

    Assessments performed at baseline and weekly through the acute phase (Week 4). (Also performed and at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase.)

    The CGI-BP scale refers to the global impression of the subject with respect to bipolar disorder. The scale rates the subject's severity of illness for mania, depression, and overall bipolar illness from 1 (least severe) to 7 (most severe).


  • Change in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Overall Illness Score at Week 30 [ Time Frame: Baseline and Week 30 ] [ Designated as safety issue: No ]

    Change from baseline to Week 30 in CGI-BP severity overall illness score, using the last observation carried forward.

    Assessments performed at baseline and weekly through the acute phase (Week 4) and at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase.

    The CGI-BP scale refers to the global impression of the subject with respect to bipolar disorder. The scale rates the subject's severity of illness for mania, depression, and overall bipolar illness from 1 (least severe) to 7 (most severe).


  • Change in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 30 [ Time Frame: Baseline and Week 30 ] [ Designated as safety issue: No ]
    Change from baseline to Week 30 in CDRS-R score, using the last observation carried forward. Assessments performed at baseline and weekly through the acute phase (Week 4) and at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase. The CDRS-R is used to diagnose depression and monitor treatment response. The interviewer rates 17 symptom areas (including those that sever as DSM-IV criteria for diagnosis of depression), among them suicidal ideation. Minimum score on the scale is 17 (better outcome). Maximum score on the scale is 113 (worse outcome or more severe symptoms).

  • Change in General Behavior Inventory Scale (GBI) Total Parent/Guardian Version Mania Score at Week 30 [ Time Frame: Baseline and Week 30 ] [ Designated as safety issue: No ]
    Change from baseline to Week 30 in GBI Total Parent/Guardian Version Mania score, using LOCF. Assessments performed at baseline and weekly through acute phase(Week 4) and Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase. GBI is a self-report inventory with 73 items focused on mood-related behaviors including depressive, hypomanic, and biphasic symptoms. One 20-item subscale was completed by parent/guardian. Symptoms rated on a 4-point Likert scale from 0 (never or hardly ever) to 3 (often or almost constantly). Minimum score 0=better outcome, maximum score 60=worse outcome.

  • Change in General Behavior Inventory Scale (GBI) Total Subject Version Mania Score at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
    Change from baseline to Week 4 in GBI Total Subject Version Mania score, using the LOCF. Assessments performed at baseline and weekly through acute phase (Week 4). (Also performed Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase.) GBI is a self-report inventory with 73 items focused on mood-related behaviors including depressive, hypomanic, and biphasic symptoms. One 20-item subscale completed by the subject. Symptoms rated on a 4-point Likert scale from 0 (never or hardly ever) to 3 (often or almost constantly). Minimum score 0=better outcome, maximum score 60=worse outcome.

  • Change in General Behavior Inventory Scale (GBI) Total Subject Version Mania Score at Week 30 [ Time Frame: Baseline and Week 30 ] [ Designated as safety issue: No ]
    Change from baseline to Week 30 in GBI Total Subject Version Mania score, using LOCF. Assessments performed at baseline and weekly through acute phase (Week 4) and Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase. GBI is a self-report inventory with 73 items focused on mood-related behaviors including depressive, hypomanic, and biphasic symptoms. One 20-item subscale completed by the subject. Symptoms rated on a 4-point Likert scale from 0 (never or hardly ever) to 3 (often or almost constantly). Minimum score of 0=better outcome, maximum score of 60=worse outcome.

  • Change in General Behavior Inventory Scale (GBI) Total Parent/Guardian Version Depression Score at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
    Change from baseline to Week 4 in GBI Total Parent/Guardian Version Depression score, using LOCF. Assessments performed at baseline and weekly through the acute phase (Week 4); also Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase. GBI is a self-report inventory with 73 items focused on mood-related behaviors including depressive, hypomanic, and biphasic symptoms. One 20-item subscale was completed by parent/guardian. Symptoms rated on 4-point Likert scale from 0 (never/hardly ever) to 3 (often/almost constantly). Minimum score 0=better outcome, maximum score 60=worse outcome.

  • Change in General Behavior Inventory Scale (GBI) Total Parent/Guardian Version Depression Score at Week 30 [ Time Frame: Baseline and Week 30 ] [ Designated as safety issue: No ]
    Change from Baseline to Week 30 in GBI Total Parent/Guardian Version Depression score, using LOCF. Assessments performed at baseline and weekly through the acute phase (Week 4); also Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase. GBI is a self-report inventory with 73 items focused on mood-related behaviors including depressive, hypomanic, and biphasic symptoms. One 20-item subscale completed by parent/guardian. Symptoms rated on 4-point Likert scale from 0 (never/hardly ever) to 3 (often/almost constantly). Minimum score 0=better outcome, maximum score 60=worse outcome.

  • Change in General Behavior Inventory Scale (GBI) Total Subject Version Depression Score at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
    Change from Baseline to Week 4 in GBI Total Subject Version Depression score, using LOCF. Assessments performed at baseline and weekly through the acute phase (Week 4); also at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase. GBI is a self-report inventory with 73 items focused on mood-related behaviors including depressive, hypomanic, and biphasic symptoms. One 20-item subscale was completed by subject. Symptoms wrated on a 4-point Likert scale from 0 (never or hardly ever) to 3 (often or almost constantly). Minimum score 0=better outcome, maximum score 60=worse outcome.

  • Change in General Behavior Inventory Scale (GBI) Total Subject Version Depression Score at Week 30 [ Time Frame: Baseline and Week 30 ] [ Designated as safety issue: No ]
    Change from baseline to Week 30 in GBI Total Subject Version Depression score, using LOCF. Assessments performed at baseline and weekly through the acute phase (Week 4); also at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase. GBI is a self-report inventory with 73 items focused on mood-related behaviors including depressive, hypomanic, and biphasic symptoms. One 20-item subscale completed by the subject. Symptoms rated on a 4-point Likert scale from 0 (never or hardly ever) to 3 (often or almost constantly). Minimum score 0=better outcome, maximum score 60=worse outcome.

  • Change in Attention Deficit Hyperactivity Disorders Rating Scale (ADHD-RS-IV) Total Score at Week 30 [ Time Frame: Baseline and Week 30 ] [ Designated as safety issue: No ]

    Change from baseline to Week 30 in ADHD-RS-IV Total score, using the LOCF.

    Assessments performed at baseline and weekly through the acute phase (Week 4) and at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase.

    The ADHD-RS-IV is an instrument both for diagnosing ADHD in children and adolescents and for assessing treatment response. The scale contains 18 items and is linked directly to DSM-IV diagnostic criteria for ADHD. The parent questionnaire on home behaviors (English) was used in this study. Minimum score of 0 = better outcome, maximum score of 54 = worse outcome.


  • Subject Response to Treatment at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]

    Percentage of Subjects with a 50% or higher reduction from baseline in Young Mania Rating Scale (Y-MRS) total score at Week 4.

    Assessments performed at baseline and weekly through the acute phase (Week 4). (Also performed at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase.)

    The Y-MRS consists of 11 items assessing the core symptoms of mania. Each item has 5 grades of severity. Minimum score on the scale is 0 (absent or normal). Maximum score on the scale is 60 (worse outcome or more severe symptoms).


  • Subject Response to Treatment at Week 30 [ Time Frame: Baseline and Week 30 ] [ Designated as safety issue: No ]

    Percentage of Subjects with a 50% or higher reduction from baseline in Y-MRS total score at Week 30.

    Assessments performed at baseline and weekly through the acute phase (Week 4) and at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase.

    The Y-MRS consists of 11 items assessing the core symptoms of mania. Each item has 5 grades of severity. Minimum score on the scale is 0 (absent or normal). Maximum score on the scale is 60 (worse outcome or more severe symptoms).


  • Change From Previous Phase in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Mania Score at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]

    Change from previous phase to Week 4 in CGI-BP mania score, using the last observation carried forward.

    Assessments performed at baseline and weekly through the acute phase (Week 4). (Also performed at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase.)

    The CGI-BP scale refers to the global impression of the subject with respect to bipolar disorder. The scale rates the change from the preceding phase score for mania, depression, and overall bipolar illness from 1 (very much improved) to 7 (very much worse).


  • Change From Previous Phase in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Mania Score at Week 30 [ Time Frame: Baseline and Week 30 ] [ Designated as safety issue: No ]

    Change from previous phase to Week 30 in CGI-BP mania score, using the last observation carried forward.

    Assessments performed at baseline and weekly through the acute phase (Week 4) and at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase.

    The CGI-BP scale refers to the global impression of the subject with respect to bipolar disorder. The scale rates the change from the preceding phase score for mania, depression, and overall bipolar illness from 1 (very much improved) to 7 (very much worse).


  • Change From Previous Phase in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Depression Score at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]

    Change from previous phase to Week 4 in CGI-BP severity depression score, using the last observation carried forward.

    Assessments performed at baseline and weekly through the acute phase (Week 4). (Also performed at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase.)

    The CGI-BP scale refers to the global impression of the subject with respect to bipolar disorder. The scale rates the change from the preceding phase score for mania, depression, and overall bipolar illness from 1 (very much improved) to 7 (very much worse).


  • Change From Previous Phase in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Depression Score at Week 30 [ Time Frame: Baseline and Week 30 ] [ Designated as safety issue: No ]

    Change from previous phase to Week 30 in CGI-BP severity depression score, using the last observation carried forward.

    Assessments performed at baseline and weekly through the acute phase (Week 4) and at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase.

    The CGI-BP scale refers to the global impression of the subject with respect to bipolar disorder. The scale rates the change from the preceding phase score for mania, depression, and overall bipolar illness from 1 (very much improved) to 7 (very much worse).


  • Change From Previous Phase in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Overall Illness Score at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]

    Change from previous phase to Week 4 in CGI-BP severity overall illness score, using the last observation carried forward.

    Assessments performed at baseline and weekly through the acute phase (Week 4). (Also performed at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase.)

    The CGI-BP scale refers to the global impression of the subject with respect to bipolar disorder. The scale rates the change from the preceding phase score for mania, depression, and overall bipolar illness from 1 (very much improved) to 7 (very much worse).


  • Change From Previous Phase in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) Severity Overall Illness Score at Week 30 [ Time Frame: Baseline and Week 30 ] [ Designated as safety issue: No ]

    Change from previous phase to Week 30 in CGI-BP severity overall illness score, using the last observation carried forward.

    Assessments performed at baseline and weekly through the acute phase (Week 4) and at Weeks 6, 8, 10, 12, 16, 20, 24, and 30 through continuation phase.

    The CGI-BP scale refers to the global impression of the subject with respect to bipolar disorder. The scale rates the change from the preceding phase score for mania, depression, and overall bipolar illness from 1 (very much improved) to 7 (very much worse).



Enrollment: 296
Study Start Date: March 2005
Study Completion Date: February 2007
Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Aripiprazole 10 mg tablet
Drug: Aripiprazole
Treatment Arm 1 (10 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, and aripiprazole 10 mg QD as the target dose starting on Day 5. Subjects remained on the 10 mg dose for the remainder of the treatment period Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
Active Comparator: 2
Aripiprazole 30 mg tablet
Drug: Aripiprazole
Treatment Arm 2 (30 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, aripiprazole 10 mg QD for 2 days, aripiprazole 15 mg QD for 2 days, aripiprazole 20 mg QD for 2 days, aripiprazole 25 mg QD for 2 days, and aripiprazole 30 mg QD as the target dose starting on Day 13. Subjects remained on the 30 mg dose for the remainder of the treatment period. Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
Placebo Comparator: 3
Placebo
Drug: placebo
Placebo tablet

  Eligibility

Ages Eligible for Study:   10 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Child and adolescent patients with bipolar I disorder, manic or mixed episode with or without psychotic features

Exclusion Criteria:

  • Patients with certain other psychological disorders
  • Patients with a co-morbid serious, uncontrolled systemic illness
  • Patients with significant risk of committing suicide
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00110461

  Hide Study Locations
Locations
United States, Arizona
Local Institution
Scottsdale, Arizona, United States
United States, Arkansas
Local Institution
Little Rock, Arkansas, United States
United States, California
Local Institution
National City, California, United States
Local Institution
Orange, California, United States
Local Institution
Pasadena, California, United States
Local Institution
Sacramento, California, United States
Local Institution
San Diego, California, United States
Local Institution
Stanford, California, United States
United States, District of Columbia
Local Institution
Washington, District of Columbia, United States
United States, Florida
Local Institution
Altamonte Springs, Florida, United States
Local Institution
Hialeah, Florida, United States
Local Institution
Jacksonville, Florida, United States
Local Institution
Miami, Florida, United States
Local Institution
North Miami, Florida, United States
Local Institution
Tampa, Florida, United States
United States, Georgia
Local Institution
Atlanta, Georgia, United States
Local Institution
Smyrna, Georgia, United States
United States, Idaho
Local Institution
Boise, Idaho, United States
United States, Illinois
Local Institution
Chicago, Illinois, United States
Local Institution
Libertyville, Illinois, United States
United States, Indiana
Local Institution
Indianapolis, Indiana, United States
United States, Kansas
Local Institution
Kansas City, Kansas, United States
Local Institution
Newton, Kansas, United States
United States, Kentucky
Local Institution
Lexington, Kentucky, United States
United States, Louisiana
Local Institution
Baton Rouge, Louisiana, United States
Local Institution
Lake Charles, Louisiana, United States
Local Institution
Shreveport, Louisiana, United States
United States, Massachusetts
Local Institution
Cambridge, Massachusetts, United States
Local Institution
Medford, Massachusetts, United States
United States, Michigan
Local Institution
Clinton Township, Michigan, United States
Local Institution
Rochester Hills, Michigan, United States
United States, Missouri
Local Institution
Kansas City, Missouri, United States
Local Institution
St. Louis, Missouri, United States
United States, Nevada
Local Institution
Las Vegas, Nevada, United States
United States, New York
Local Institution
Elmsford, New York, United States
Local Institution
New York City, New York, United States
Local Institution
Rochester, New York, United States
Local Institution
Stony Brook, New York, United States
United States, Ohio
Local Institution
Cincinnati, Ohio, United States
Local Institution
Cleveland, Ohio, United States
United States, Oklahoma
Local Institution
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Local Institution
Philadelphia, Pennsylvania, United States
United States, South Carolina
Local Institution
Charleston, South Carolina, United States
United States, Tennessee
Local Institution
Memphis, Tennessee, United States
United States, Texas
Local Institution
Bellaire, Texas, United States
Local Institution
Fort Worth, Texas, United States
Local Institution
Houston, Texas, United States
Local Institution
San Antonio, Texas, United States
United States, Virginia
Local Institution
Herndon, Virginia, United States
Local Institution
Richmond, Virginia, United States
United States, Washington
Local Institution
Kirkland, Washington, United States
Local Institution
Spokane, Washington, United States
United States, Wisconsin
Local Institution
Milwaukee, Wisconsin, United States
Sponsors and Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
Investigators
Study Director: Margaretta Nyilas, MD Otsuka Pharmaceutical Development & Commercialization, Inc.
  More Information

No publications provided by Otsuka Pharmaceutical Development & Commercialization, Inc.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Arifulla Khan, MD, Northwest Clinical Research Center
ClinicalTrials.gov Identifier: NCT00110461     History of Changes
Other Study ID Numbers: 31-03-240
Study First Received: May 9, 2005
Results First Received: August 11, 2011
Last Updated: April 19, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:
Aripiprazole
Bipolar I Disorder, Manic or Mixed Episode with or without Psychotic Features

Additional relevant MeSH terms:
Bipolar Disorder
Disease
Affective Disorders, Psychotic
Mental Disorders
Mood Disorders
Pathologic Processes
Aripiprazole
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents

ClinicalTrials.gov processed this record on October 30, 2014